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Radiosensitisation enhancement effect of BrUdR and Ta2O5 NSPs in 
combination with 5-Fluorouracil antimetabolite in kilovoltage and megavoltage 
radiation 
Abstract 
This article demonstrates in vitro a synergistic effect on 9L gliosarcoma cells when exposed to 
bromodeoxyuridine (BrUdR) and a low concentration (100 times lower than the IC50) of 5-Fluorouracil 
(5-FU), in combination with x-ray irradiation. The synergy is brought about by several important factors 
including the x-ray beam energy, atomic number of the BrUdR (Z = 35), effectiveness of 5-FU in reducing 
the available repair processes and distribution of the BrUdR in and around the 9L cells (32% of the total 
substitution of BrUdR for thymidine into nucleus DNA). Our results show that the synergistic effect, 
evident in an optimised 125 kVp x-ray field, leads to a radiosensitisation enhancement ratio at the 10% 
survival level (SER10%) of 2.11. We highlight the importance of the aforementioned factors by similarly 
performed experiments for higher Z (Z = 73) tantalum pentoxide nano-structured particles (Ta2O5 NSPs) 
that are substituted for the BrUdR in larger concentration (~10 times). In the Ta2O5 NSPs experiments, no 
synergistic effect is observed in the kVp irradiation with optimal energy spectrum even though the 
effective Z and NSP concentration is much higher than for BrUdR. All experiments were repeated using a 
MV x-ray irradiation field and no synergistic effect is observed for either the BrUdR or Ta2O5 case. We 
therefore hypothesise that the synergistic outcome is due to more drastic and complex damages induced 
by BrUdR under the exposure of kVp radiation. Such damages are achieved by the localisation of the 
BrUdR in the DNA and the high LET (very short range) secondary electrons in combination with the 5-FU. 
In order to achieve similar synergistic effects in the more clinically relevant x-ray energy field the 
concentration of the high Z material needs to be greater in order to create a higher LET electron 
environment. 
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ABSTRACT  14 
 15 
This article demonstrates in vitro a synergistic effect on 9L gliosarcoma cells when exposed to 16 
bromodeoxyuridine (BrUdR) and a low concentration (100 times lower than the IC50) of 5-Fluorouracil (5-17 
FU), in combination with X-ray irradiation. The synergy is brought about by several important factors 18 
including the X-ray beam energy, atomic number of the BrUdR (Z=35), effectiveness of 5-FU in reducing 19 
the available repair processes and distribution of the BrUdR in and around the 9L cells (32% of the total 20 
substitution of BrUdR for thymidine into nucleus DNA). Our results show that the synergistic effect, evident 21 
in an optimised 125 kVp X-ray field, leads to a radiosensitisation enhancement ratio at the 10% survival 22 
level (SER10%) of 2.11. We highlight the importance of the aforementioned factors by similarly performed 23 
experiments for higher Z (Z=73) tantalum pentoxide nano-structured particles (Ta2O5 NSPs) that are 24 
substituted for the BrUdR in larger concentration (~10 times). In the Ta2O5 NSPs experiments, no synergistic 25 
effect is observed in the kVp irradiation with optimal energy spectrum even though the effective Z and NSP 26 
concentration is much higher than for BrUdR. All experiments were repeated using a MV X-ray irradiation 27 
field and no synergistic effect is observed for either the BrUdR or Ta2O5 case. We therefore hypothesise that 28 
the synergistic outcome is due to more drastic and complex damages induced by BrUdR under the exposure 29 
of kVp radiation. Such damages are achieved by the localisation of the BrUdR in the DNA and the high LET 30 
(very short range) secondary electrons in combination with the 5-FU. In order to achieve similar synergistic 31 
effects in the more clinically relevant X-ray energy field the concentration of the high Z material needs to be 32 
greater in order to create a higher LET electron environment. 33 
 34 
 35 
INTRODUCTION  36 
 37 
Most of the recent technological advances in radiation oncology are linked with developing state-of-the-art 38 
techniques that allow for better geometrically targeting of lesions. These techniques include intensity 39 
modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic 40 
ablative body radiation therapy, and proton therapy (MacDonald et al 2007, Nutting et al 2011, Van de 41 
Water et al 2011). Their ultimate goal is to provide better dose conformity to the tumours while sparing the 42 
surrounding healthy tissue, ultimately allowing dose escalation, locally creating more DNA damages to the 43 
cancerous cells. A similar outcome can be achieved by introducing a high atomic number (Z) material into 44 
the lesions (Pignol et al 2003, Rahman et al 2009). This area is currently the subject of many investigations 45 
to enhance the impact of the ionising radiation dose on the target (Antosh et al 2015).  46 
 47 






































































Making a tumour more sensitive to radiotherapy and maximise the absorbed dose in malignant cells is also a 48 
primary goal of chemotherapy. Chemotherapy is the utilisation of anti-cancer drugs to inhibit tumour growth 49 
(cytostatic agents) or destroy the cancerous cells (cytotoxic agents). The drug treatment can consist of only 50 
one or multiple drugs delivered at the same time. Moreover, this treatment can also be administered before, 51 
after, or concurrently with radiation therapy. 5-Fluorouracil (5-FU) is one chemotherapy drug that has been 52 
proven to be clinically effective. In particular, this drug has been found to specifically target the folate cycle 53 
so as to inhibit the DNA synthesis (Longley et al 2003).  54 
 55 
To date, chemoradiotherapy with antimetabolites such as 5-FU has become a standard therapy for the 56 
treatment of a wide range of solid tumours, such as esophageal carcinoma, head and neck cancer, rectal 57 
cancer and gliosarcoma (Bedenne et al 2007, Adelstein et al 2003, Baglan et al 2002, Damodaran et al 58 
2013). Chemoradiotherapy can therefore be considered a marriage between chemotherapy and radiotherapy, 59 
with the 5-FU drug being one of the most commonly used anticancer drugs utilised in this marriage, 60 
especially where the local regional control is often required (Harada et al 2006). An antimetabolite has the 61 
capability to inhibit the post-radiation damage repair (Lehnert 2014). In addition, agents that target the 62 
radioresistant S- phase of the cell cycle such as 5-FU, may be effective in preventing the instigation of the 63 
growth of the tumour cell (Lehnert 2014). 5-FU drug is integrated into nucleoside metabolism, causing the 64 
suppression of the RNA and the DNA replication (Ooyama et al 2007). Moreover the 5-FU drug is cell cycle 65 
dependent and it will most likely affect the radiation impact on rapidly proliferating tissues such as high-66 
grade gliomas. Despite a plethora of research reporting the effectiveness of the 5-FU drug, in clinical 67 
treatment, the response rates are modest due to its high cytotoxicity and less therapeutic efficacy in the 68 
treatment of advance disease (Ilson 2008). The 5-FU drug, is therefore, often delivered in conjunction with 69 
other agents during radiation treatment to amplify its therapeutic impact on tumours. 70 
 71 
Bromodeoxyuridine (BrUdR) is a halogenated pyrimidine that is known to sensitise cells to ionising 72 
radiation (Sano et al 1968, Dewey and Humphrey 1965). It is a classic radiosensitiser used in radiation 73 
treatment that display low Linear Energy Transfer (LET) such as x-rays and gamma-rays. Its role in 74 
radiosensitisation is not clear but its presence in the DNA strand seems to render the DNA to be more 75 
susceptible to radiation. This, in turn, leads to the observation of enhanced radiosensitivity of the carrier 76 
cells. The hypothesis among studies documented is that the incorporated BrUdR produce denser ionisation 77 
tracks that cause cluster DNA damage, together with the radicals formed by the low-LET ionising radiation 78 
(Epstein et al 1992). This clustered DNA damage leads to an increase in the relative biological effectiveness 79 
(RBE), making it as effective as high-LET radiation. There is also evidence suggesting that the 80 
radiosensitisation enhancing effect of BrUdR is through inhibiting the repair of damaged DNA and the 81 
fixation of radiation-induced damage (Iliakis et al 1989; Wang et al 1994).  82 
 83 
Both Bromodeoxyuridine (BrUdR, ZBr = 35) and Iododeoxyuridine (IUdR, ZI = 53) compounds have been 84 
shown to sensitise cells to ionising radiation (Doiron et al 1999, Oktaria et al 2015, Corde et al 2004). 85 
Radio-sensitisers with high Z compositions, such as the aforementioned two agents, have been shown to 86 
cause more tissue damage by increasing the absorption or scattering of the radiation, as well as causing more 87 
local energy deposition via the overproduction of low energy secondary electrons (Brown et al 2014). 88 
 89 
The simultaneous addition of the 5-FU drug and the BrUdR had been shown to significantly enhance the 90 
uptake of BrUdR into the cerebral tumour cell nuclei (Hoshino and Sano 1969). Moreover, they also found 91 
the combination of the 5-FU drug and the BrUdR has resulted in an increase in the irradiation sensitisation 92 
effects (Hoshino and Sano 1969). A possible explanation for their findings, according to Hoshino and Sano 93 
(1969) was that the presence of 5-FU in the DNA inhibits the biosynthetic mechanism, therefore forcing the 94 
cells in the mitotic stage to uptake thymidine analogue, BrUdR, in order to supply sufficient thymidine 95 






































































required to duplicate the DNA cells. This explanation is based on their assumption that the cells do not 96 
voluntarily incorporate BrUdR during their mitosis because they can synthesise the thymidine required for 97 
this DNA duplication. Due to this area of research being relatively unexplored, more studies are required to 98 
elucidate the relationship between the 5-FU drug and the BrUdR compound in radiation treatment, as well as 99 
the influence of the radiation energy.       100 
 101 
Recently cancer immunotherapy has become an intensely active research field (Shao et al 2014, Emens et al 102 
2017, Restifo et al 2016). Current strategies for immunomodulation have addressed the effectiveness of 103 
immunotherapy; however, there are still many fundamental challenges. These challenges include nonspecific 104 
modulation that may result in an unfavourable cytotoxic system while specific modulation methods may 105 
generate an insufficient therapeutic response on some target. Moreover, most immunotherapies, particularly 106 
those directed against solid cancers, have only benefited a small minority of patients (Velpurisiva et al 2017, 107 
Restifo et al 2016). Recent research using nanoparticles for cancer immunotherapy has demonstrated that 108 
immunotherapy generates significantly more sustained and robust anticancer effects when they are 109 
effectively bound in nanoparticles (Goldberg 2015). Nonetheless, the success of the integration of 110 
nanotechnology with cancer immunotherapy lies in finding the compatible nanoparticle candidate that has 111 
the capability to facilitate this therapy (Saleh and Shojaosadati 2016, Velpurisiva et al 2017). 112 
 113 
Nanotechnology is a vastly expanding field with numerous and diverse applications due to the unique 114 
properties of the nanoparticles. The most distinguishable characteristic of the nanoparticles is that the 115 
properties that these particles possess are often of no resemblance to that of the equivalent bulk material 116 
(Buzea et al 2007). The significant reduction in size associated with the nanoparticles leads to a high particle 117 
number per unit mass as well as a much greater surface area (Buzea et al 2007). In radiation oncology, 118 
nanoparticles with high Z properties make them potentially ideal candidates as radio-sensitisers. An example 119 
of this is the use of gold nanoparticles in the radiobiological dose enhancement (Rahman et al 2009, Hainfeld 120 
et al 2008). The implementation of gold nanoparticles has already reached clinical trials (for example, see 121 
Libutti et al 2010). Although this dose enhancement effect is achieved with the gold nanoparticles, the 122 
optimal energy for dose enhancement is in the kV radiation. This poses a drawback as current clinical trials 123 
with gold nanoparticles are performed in the MV energy field. The use of tantalum pentoxide- 124 
nanostructured particles (Ta2O5 NSPs) is currently being studied as a radiation sensitiser based on its high-125 
mass energy absorption coefficient, and is novel in the field of nanomedicine. Ta2O5 NSPs have been 126 
experimentally shown to cause cell sensitisation in a higher energy MV radiation field (Brown et al 2017). 127 
This study found that when the 9L cells containing Ta2O5 NSPs exposed to the radiation, a higher degree of 128 
damage (due to dose enhancement) is observed in comparison to the irradiated cells that were not treated by 129 
the Ta2O5 NSPs.  130 
 131 
Given a mild to moderate therapeutic effectiveness in chemoradiotherapy with antimetabolites, investigation 132 
into improving the therapeutic effectiveness of radiation via radiation enhancers have been the focus of many 133 
researchers in this field. Research has long demonstrated that the delivered dose to the target was increased 134 
when a high Z material was in the targeted zone (Spiers 1949). Hence, a comprehensive breakthrough for 135 
local treatment and radiotherapy is dependent on the possibility of depositing significant energy within the 136 
tumour mass.   137 
 138 
There is much evidence to suggest an effectiveness of both BrUdR and Ta2O5 NSPs in the cancer treatment 139 
research (Hoshino T et al 1969, Brown et al 2014). However, to date, there has been no study published that 140 
compared the effectiveness between BrUdR and Ta2O5 NSPs in treating the cancerous cells, when 141 
simultaneously combined with 5-FU anti-cancer drug. The finding of this study can potentially provide a 142 





































































guide regarding the future direction of the cancer research. Moreover, it can also lead to a significant 143 
improvement of the treatment outcome as well as the therapeutic effectiveness.  144 
 145 
Among the various models of brain tumour, the radioresistant 9L gliosarcoma model is most commonly used 146 
to replicate the glioblastoma multiforme (Ghods et al 2007). This model has been established as a valid 147 
experimental model for brain tumour therapy as it can best mimic the rapid growth and atrophy of 148 
intracerebral tumours (Ghods et al 2007). This subsequently allows for efficient testing of both 149 
chemotherapeutic and nanotechnology- based therapies. 150 
 151 
This study primarily aims to investigate the radiation sensitisation effect of two different high Z elements -152 
when combined with the 5-FU drug at kilovoltage (kVp) and megavoltage (MV) x-ray radiation energies. 153 
Any change in sensitisation measured between the two radiation energies is of particular interest especially 154 
in the context of the respective localisation of the elements within the whole target cell volume. The goal of 155 
this approach is to capitalise on their radiosensitisation properties in an attempt to achieve a synergistic effect 156 
on radioresistance 9L gliosarcoma cells when combine with 5-FU. 157 
 158 
 159 
METHODS AND MATERIALS 160 
 161 
Cell Culture 162 
 163 
Gs-9L rat gliosarcoma cells originated from an N-nitrosomethylurea-induced tumour and were established 164 
by the European Collection of Cell Cultures. Cell cultures were maintain in Dulbecco’s Modified Eagle 165 
medium (DMEM, Gibco BRL, AUS) containing 10% (v/v) fetal bovine serum (FBS, Sigma-Aldrich, MO, 166 
USA) and 1% (v/v) penicillin/streptomycin (Pen Strep, Gibco BRL, AUS) in a T75 cm2 BD FalconTM Tissue 167 
Culture Flasks (Franklin Lakes, NJ, USA) and incubated at 37°C in a humidified and 5% (v/v) CO2 168 
atmosphere.  169 
 170 
Exposure to pharmaceutical agents  171 
 172 
1×105 cells were seeded in a T12.5 cm2 Flask and incubated for 48 hours to allow the cells to attach and 173 
divide. DMEM was replaced and the cells were then cultured in a 0.01 µM 5-FU and/or 10 µM BrUdR 174 
(Sigma-Aldrich, MO, USA) for 2 doubling times before radiation exposure. Ta2O5 NSPs were synthesised by 175 
our laboratory using a thermal oxidation reaction. Ta2O5 nanoparticles were suspended in phosphate buffered 176 
saline (PBS) (without calcium and magnesium ions) and sonicated before being added to the cultured cells 177 
24 hours prior to irradiation at a concentration of 113 µM (50 µg/ml).  178 
 179 
Flow cytometric Measurement of BrUdR incorporation in DNA 180 
 181 
After the cells are exposed to BrUdR for 2 doubling times, they were taken for the preparation prior to the 182 
measurement using a Becton Dickinson fluorescence-activated cell sorting (FACS) flow cytometer (BD LSR 183 
II; BD Biosciences, USA). The cells were stained with anti-BrUdR mouse monoclonal antibody (Clone 184 
MoBU-1) conjugated to Alexa Fluor 488 dye (highly specific for this nucleoside analogue) from Molecular 185 
Probe (Invitrogen, Carlsbad, CA, USA). Cell’s DNA incorporating BrUdR was detected using this 186 
fluorescently labelled anti-BrUdR antibodies. This compound staining optimised for cellular labelling and 187 
detection. The stained nuclei were measured and analysed with flow cytometer with excitation at 488 nm.  188 
The BrUdR labelling index (LI) is calculated. The BrUdR LI is the ratio of the number of BrUdR-positive 189 
cells to the total number of cells. 190 







































































Flow cytometric Measurement of Internalisation of Ta2O5 NSPs  192 
 193 
After exposing of the cells to the NSPs for 24 hours, the cells were harvested, centrifuged at 1500 rpm for 5 194 




 free (DPBS, 195 
Gibco BRL, AUS).  Flow cytometric measurements were performed with the forward scatter (FSC) and side 196 
scatter (SSC). A minimum of 1×104 cells were analysed from the harvested cells sample. 197 
 198 
Confocal Microscope Imaging of Internalisation of Ta2O5 NSPs 199 
 200 
The cells were grown and cultured with NSPs in a TMLab-TekTMII Chamber SlideTMSystem 4 wells (growth 201 
area = 1.8 cm2) (Thermos-Scientific). After exposure to NSPs for 24 hours, light and fluorescence 202 
microscope images were obtained using a Leica confocal laser scanning microscope (Leica TCS SP5 203 
Advanced System – UV-VIS-IR and X1-Port Access with SMD FCS and CO2 incubation chamber, 204 
Germany) with oil immersion objective lens and the accompany images manager software Leica Application 205 
Suite Advanced Fluorescence (LAS AF, v.2.6.1-7314, Germany). 206 
  207 
Irradiation procedure and set up 208 
 209 
Confluent monolayers cell cultures were irradiated in T12.5 cm2 flasks using a Nucletron Oldelft Therapax 210 
DXT 300 Series 3 Orthovoltage unit (Nucletron B.V., Veenendaal, The Netherlands) and an Elekta Axesse 211 
linear accelerator with beam modulator (Elekta AB, Kungstensgatan, Stockholm, Sweden) at the radiation 212 
oncology department of Prince of Wales Hospital (Randwick, NSW, Australia). Selected doses (1, 2, 3, 5 213 
and 8 Gy) were delivered at the cell level in single fraction at room temperature and in full scatter conditions, 214 
with dose-rates of 0.7 and 5 Gy/min for kilovoltage and megavoltage experiments respectively. This 215 
difference in dose rates has been shown by Oktaria (2017) to have insignificant effect on the survival of 9L 216 
cells. Moreover, the selected radiation energies have similar RBE on 9L surviving fraction. 217 
 218 
For megavoltage (MV) irradiation, the energy selected was 10 MV and cells monolayers were at 2.2 cm 219 
depth (depth of maximum dose), 102.2 cm from the source. For kilovoltage (kV) X-ray irradiation, cells 220 
monolayers were either facing the applicator, 50 cm from the source or at 5 mm depth, 52 cm from the 221 
source depending on flasks orientation. The additional filter was chosen to provide a photon energy spectrum 222 
whose effective energy approximates the maximum mass energy absorption for the high Z target relative to 223 
water (as shown in Figures 1a and 1b).  224 
 225 
 226 







































































Figure 1. Ratio of the total mass energy absorption coefficient of (a) Bromine and (b) Tantalum to water as a 227 
function of energy (corresponding to the y-axis on the left). Output spectrum of an orthovoltage X-ray unit 228 
operating at (a) 125 kVp and (b) 150 kVp is also shown (corresponding to the y-axis on the right). The data 229 
for the output spectrum was generated using SpekCalc (Poludniowski et al 2009).  230 
 231 
For BrUdR experiments, flasks were irradiated vertically the Pantak unit was operating at a peak voltage of 232 
125 kVp and 20 mA with additional filtration of 0.1 mm Cu and 2.5 mm Al (HVL = 6.70mm Al). For Ta2O5 233 
NSPs experiments, flasks were irradiated horizontally and the unit was chosen to operate at 150 kVp and 20 234 
mA with additional filtration of 0.35 mm of Cu and 1.5 mm of Al (HVL = 0.67mm Cu). Beams were 235 
calibrated as per international protocols for absolute dosimetry and relative dosimetry data were applied to 236 
correct for changes compared to reference conditions. More details of the irradiation conditions can be found 237 
in (Oktaria et al 2015 and Brown et al 2017)   238 
 239 
In vitro assessment of radiation therapy effect and data analysis 240 
 241 
Cells were plated after irradiation at low densities in 100 mm diameter Petri dishes containing 10 ml of 242 
complete DMEM. Depending on the prescribed dose, each irradiated sample involved a minimum of three 243 
cells densities with triplicate dishes for each density. After 15 doubling times, the colonies were fixed and 244 
stained with a mixture solution of 25% crystal violet and 75% ethanol. The cell clonogenic surviving fraction 245 




The two fit parameters α (Gy-1) and β (Gy-2) are determined by using the OriginLab graphing & analysis 248 
software nonlinear curve-fitting algorithm. The sensitisation enhancement ratio at the 10% survival level 249 
(SER10%) is determined by taking the ratio of doses to achieve 10% cell survival for cells without treatment 250 
(radiation alone) to those with treatment(s) (5-FU, BrUdR, Ta2O5 NSPs or combinations). The errors bars are 251 
standard errors of the means (SEM). The assays of all irradiation treatment conditions (with or without 252 





Detection of BrUdR incorporation in DNA 258 
 259 
The flow cytometer measures 32% of the total substitution of BrUdR for thymidine into nucleus DNA (see 260 
Figures 2.a and 2.b). However, the presence of 5-FU that served to inhibit thymidine synthesis did not 261 
increase the uptake of the BrUdR into cells DNA (see Figures 2.b and 2.c).  262 
 263 








































































Figure 2. Flow cytometric measurements of the amount of Bromide from a 10 µM concentration that is 265 
accessible to the DNA and is displayed in the graphs of the total DNA content (red fluorescence-575/26-A) 266 
versus amount of incorporated BrUdR (green fluorescence-515/20-A) (a) control sample (b) cells incubated 267 
with 10 µM BrUdR (c) cells incubated with 10 µM BrUdR and 0.01 µM 5-FU for 2 doubling times before 268 
added fluorescently labelled anti-BrUdR antibodies prior to measurement. 269 
   270 
Internalisation of Ta2O5 NSPs 271 
 272 
 273 
Figure 3. Flow cytometric measurements of the amount of internalisation of Ta2O5 NSPs in cells (a) control 274 
sample set of cells that was incubated without NSPs (b) cells that incubated with NSPs 24 hours prior to 275 
measurement. 276 
  277 








































































Figure 4. Confocal microscope images of (a) 9L cells that were incubated without NSPs (b) 9L cells that 279 
incubated with NSPs 24 hours prior to imaging.  280 
 281 
The changed in mean side scattering (SSC) and mean forward scattering (FSC) represents the relative change 282 
in granularity and size of the cell, respectively. The gating is restricted between 60 % - 100 %, to eliminate 283 
dead cells and debris from analysis (Figure 3). From this the amount of internalisation of Ta2O5 NSPs on the 284 
cells is measured to increase the cellular granularity by 45%. This measurement is used as a marker for 285 
internalisation of NSPs. Figure 4 (b) showed a relatively even distribution of 113 μM of Ta2O5 NSPs. It 286 
shows that the NSPs are positioned in the culture in possible three manners; inside the cells, on the cells and 287 
in close proximity to the cells.  288 
 289 
Cytotoxicity of pharmaceutical agents on 9L Cells  290 
  291 
 292 
Figure 5. Normalised surviving fractions of 9L cells with and without the individual components of the 293 
combination (i.e. 5-FU + BrUdR and 5-FU + Ta2O5 NSPs) of 3 independent experiments. Errors bars 294 
represent the SEM. 295 
 296 






































































The cytotoxicity of 5-FU on 9L cells is demonstrated by a surviving fraction of 68 ± 7%. The cytotoxicity of 297 
BrUdR on the cells resulted in a cell surviving fraction of 71 ± 2%. The Ta2O5 NSPs displayed modest 298 
toxicity on the cells. The cells surviving fraction after 24 hours exposure to 50 µg/ml of Ta2O5 NSPs was 299 
determined to be 82 ± 3%. When each of the aforementioned high-Z materials coexist with 5-FU, it 300 
marginally increased the toxicity, although remained within the uncertainties (see Figure 5). The cytotoxicity 301 
of the individual combination of BrUdR and Ta2O5 NSPs with 5-FU resulted in the cells surviving fractions 302 
of 65 ± 8% and 71 ± 5%, respectively.  303 
 304 
Comparison of 5-FU + BrUdR with 5-FU + Ta205 NSPs with kV x-ray 305 
 306 
 307 
Figure 6. Dose effect relationship of 9L cells irradiated with orthovoltage x-rays and pre-exposed with (a) 5-308 
FU + BrUdR irradiated with 125 kVp x-ray and (b) 5-FU + Ta2O5 NSPs irradiated with 150 kVp x-ray with 309 
and without the individual components of the combination, of 3 independent experiments. Errors bars 310 
represent the SEM.  311 
 312 
Table 1. Radiation sensitivity parameters for 125 kVp irradiated gliosarcoma  313 
cancer cell line treated with 5-FU + BrUdR with and without the individual  314 
components of the combination. 315 
        
  α (Gy-1) β (Gy-2) SER10% 
    
Control 0.21 ± 0.03 0.002 ± 0.006 N/A 
5-FU (0.01 μM) 0.19 ± 0.02 0.006 ± 0.003 1 
BrUdR (10 μM) 0.29 ± 0.04 0.011 ± 0.006 1.58 
5-FU (0.01 μM)+BrUdR (10 μM) 0.47 ± 0.03 0.007 ± 0.005 2.11 
α and β are radiosensitivity parameters. Values are presented as mean ± SD.  

















































































Table 2. Radiation sensitivity parameters for 150 kVp irradiated gliosarcoma cancer  325 
cell line treated with 5-FU + Ta2O5 NSPs with and without the individual components  326 
of the combination. 327 
        
  α (Gy-1) β (Gy-2) SER10% 
   
 
Control 0.27 ± 0.04 0.004 ± 0.007 N/A 
5-FU (0.01 μM) 0.14 ± 0.03 0.022 ± 0.004 1 
Ta2O5 NSPs (113 μM) 0.31 ± 0.01 N/A 1.03 
5-FU (0.01 μM)+Ta2O5 NSPs  
(113 μM) 
0.35 ± 0.02 N/A 1.1 
α and β are radiosensitivity parameters. Values are presented as mean ± SD.  
SER10% = sensitisation enhancement ratio at 10% surviving fraction.  
 328 
The irradiated 9L cells pre-exposed to 0.01 µM 5-FU with and without 10 µM BrUdR or 113 µM of Ta2O5 329 
NSPs resulted in the survival curves presented in Figure 6. The 5-FU demonstrated no enhanced sensitisation 330 
effect of the x-ray irradiation on the clonogenic survival of 9L cells in both 150 kVp and in the 125 kVp. 331 
BrUdR-incorporated cells significantly enhanced the biological effect of the X-ray irradiation compared with 332 
the Ta2O5 NSPs-incorporated cells (Figure 6). The SF were substantially decreased with the cells treated with 333 
5-FU+BrUdR compared to the sensitise effect of their individual components. This significant degree of 334 
radiation dose enhancement bestowed a synergistic effect as a result. The increase in the α and β parameters 335 
in the linear quadratic curves can be drawn from the Figure 6a and are displayed in Table 1. Conversely, 336 
similar effects were not observed with Ta2O5 NSPs treated cells irradiated at the 150 kVp. The survival curve 337 
of Ta2O5 NSPs displayed no radiosensitising enhancement from the control curve with 150 kVp x-ray. In 338 
particular, the Ta2O5 NSPs were irradiated in the optimum energy spectrum, however this seems to be 339 
ineffective in increasing radiosensitisation. Nevertheless, the combination of 5-FU and Ta2O5 NSPs exhibited 340 
radiation enhancement which can be seen from Figure 6b and the increase in α and decrease in β components 341 
of the linear quadratic curves is evident on Table 2. 342 
   343 
Comparison of 5-FU + BrUdR with 5-FU + Ta2O5 NSPs with MV x-ray 344 
 345 
346 
Figure 7. Dose effect relationship of 9L cells irradiated with 10MV x-rays and pre-exposed with  (a) 5-FU + 347 
BrUdR and (b) 5-FU + Ta2O5 NSPs with and without the individual components of the combination, of 3 348 
independent experiments. Errors bars represent the SEM. 349 








































































Table 3. Radiation sensitivity parameters for 10 MV irradiated gliosarcoma  351 
cancer cell line treated with 5-FU + BrUdR with and without the individual  352 
components of the combinations. 353 
        
  α (Gy-1) β (Gy-2) SER10% 
    Control 0.19 ± 0.01 0.010 ± 0.002 N/A 
5-FU (0.01 μM) 0.17 ± 0.01 0.013 ± 0.002 1 
BrUdR (10 μM) 0.39 ± 0.03 0.006 ± 0.001 1.53 
5-FU (0.01 μM)+BrUdR (10 μM) 0.43 ± 0.02 N/A 1.61 
α and β are radiosensitivity parameters. Values are presented as mean ± SD.  
SER10% = sensitisation enhancement ratio at 10% surviving fraction. 
 354 
Table 4. Radiation sensitivity parameters for 10 MV irradiated gliosarcoma cancer  355 
cell line treated with 5-FU + Ta2O5 NSPs with and without the individual components 356 
 of the combinations. 357 
        
  α (Gy-1) β (Gy-2) SER10% 
   
 
Control 0.19 ± 0.01 0.010 ± 0.002 N/A 
5-FU (0.01 μM) 0.17 ± 0.01 0.013 ± 0.002 1 
Ta2O5 NSPs (113 μM) 0.32 ± 0.01 0.005 ± 0.002 1.29 
5-FU (0.01 μM)+Ta2O5 NSPs 
(113 μM) 
0.37 ± 0.01 N/A 1.35 
α and β are radiosensitivity parameters. Values are presented as mean ± SD. 
SER10% = sensitisation enhancement ratio at 10% surviving fraction.    
 358 
In view of the clinical importance of MV radiation therapy, comparisons of the two combinations (5-359 
FU+BrUdR and 5-FU+Ta2O5 NSPs) were also assessed using 10MV. Similar to that observed in kilovoltage 360 
radiation, 5-FU demonstrated no effect in sensitising cells as shown in the Figure 7. The radiosensitisation 361 
enhancement in the survival curve of the BrUdR and Ta2O5 NSPs were observed in this higher irradiated 362 
energy. The results for the 9L cells treated with the combination (i.e. 5-FU+BrUdR or 5-FU+Ta2O5 NSPs) 363 
administered concomitantly with 10 MV irradiation showed a cell kill greater than what achieved by its 364 
individual components alone. Figure 7 clearly illustrated that neither the combination attained statistically 365 
significant greater effects than their respectively high-Z standalone results. However, their survival curves 366 
displayed absolutely no shoulder, suggesting some increase in complex lethal damage from secondary 367 
electrons due to the inhibiting of the cellular repair, instigated by the 5-FU. In addition, significant increases 368 
of α value were obtained and the quadratic parameter β decreased to none for both combinations (see Table 3 369 
and 4). This increase in α and decrease in β indicates a more effective cell kill which is significant from the 370 














































































DISCUSSION  378 
 379 
Concurrent chemoradiotherapy is an effective component of modern cancer therapy, but it is still ultimately 380 
limited by the fact that some cancer cells such as 9L cells are resistant to ionising radiation and 381 
chemotherapy. Hence, there is a need to introduced high-Z elements into the tumour to increase the 382 
probability of ionisation events leading to enhanced deposition of energy to destroy tumour cells.   383 
 384 
BrUdR and Ta2O5 NSPs subcellular localisation demonstrates fundamental differences  385 
 386 
BrUdR is a halogenated pyrimidine that has a similar chemical structure with the natural pyrimidines and 387 
thus can be incorporated into the DNA chains during the DNA synthesising phase. BrUdR is therefore a 388 
provider of high Z-radiosensitiser atoms (i.e. bromine) which are incorporated into DNA. 32% of the DNA 389 
was found to be substituted by BrUdR, halogenated thymidine analogues. This finding is fundamental as the 390 
degree to which the cells are sensitised to the radiation is dependent on the amount of the halogenated 391 
pyrimidine being incorporated into the DNA. In accordance with our findings, a study conducted by Aoyama 392 
et al (1964) also found the BrUdR to be 33% using a similar BrUdR concentration. The remaining amount of 393 
Bromide is distributed in the cell nucleus, cytoplasm, and outside the cells. 394 
 395 
In the case of Ta2O5 NSPs, due to its larger size, it is only able to infiltrate into the cytoplasm. The results of 396 
this study indicate an increase of forty-five percent in the cellular granularity. This suggested an uptake of 397 
NSPs in the treated cells in comparison to the untreated cells. Additionally, the confocal image showed that 398 
the majority of the NSPs were either internalised or in close proximity to the cell cytoplasm. 399 
 400 
Taken together, the incorporation of 32% Bromide into the DNA appeared to be the main catalyst for the 401 
results observed, and is due to the double strand breaks (DSB) in the DNA when combined with radiation in 402 
kVp. This appeared to also be true for the other Bromide that was inaccessible to the DNA when in the 403 
presence of radiation using MV. In comparison, Ta2O5 NSPs was observed to exhibit radiation enhancement 404 
only when using MV. This is because Ta2O5 NSPs is found situated outside the cell nucleus. Additionally, 405 
Ta2O5 NSPs form agglomerates that may absorb secondary electrons (Brown et al 2014). 406 
 407 
Minimal cytotoxicity effect of the BrUdR + 5-FU and Ta2O5 NSPs + 5-FU on the cells is maintained in 408 
order to maximise the use of x-ray radiation in targeting the cancerous cells 409 
 410 
The surviving fraction of each individual agent is relatively high (see Figure 5). It is important that high cell 411 
surviving fraction is maintained in the combination (i.e. BrUdR + 5FU and Ta2O5 NSPs + 5-FU) to minimise 412 
unirradiated cell toxicity. In the clinical treatment, these cells may be healthy cells that are surrounding the 413 
tumour target. For this reason, the primary killing mechanism needs to originate from the x-ray radiation. 414 
 415 
Radiation sensitization enhancements strongly depends on radiation energy and high Z localisation 416 
 417 
The interaction of BrUdR with x-rays results in the emission of Auger electrons, photoelectrons, Compton 418 
scattering electrons, and electron-positron pair production. These electrons range from the nanometer-scale 419 
to several micrometers. Whilst the interaction of BrUdR-treated cells with x-rays has a higher interaction 420 
cross section at lower radiation energy (kV), using higher energy (10 MV) photons has demonstrated to be 421 
just as effective. Evidence for this was illustrated in Figure 7 which reflects the SER10% values of 1.58 and 422 
1.53 respectively. The result obtained in this experiment for the radiosensitisation effect of BrUdR using the 423 
kV energies is incongruent with that of Aoyama et al (1964).   424 
 425 





































































An increase in the α component and the α/β ratio in the LQM suggests a greater early response for the 426 
BrUdR exposed 9L cells to the MV irradiation, when fit to the SF data at MV compared to kVp. The 427 
increase in α/β ratio was also contributed by the decrease in the quadratic β parameter. This positive result 428 
for BrUdR in the MV irradiated energies could inform the future the clinical potential of BrUdR.   429 
 430 
The increase in α and decrease in the β achieved for BrUdR in the 10MV is most likely due to the interaction 431 
between the BrUdR compound surrounding the cell nucleus and the Compton scattering electron. Compton 432 
scattering electron is the dominant interactive mechanism for MV photons in water. This interaction may 433 
have resulted in significant number of secondary electrons being formed within a cell. Additionally, the back 434 
scattered photons (~120 keV median energy) was expected to interact with the BrUdR compound, 435 
contributing to a greater number of secondary electrons being created. Together, forming of these secondary 436 
electrons meant a more densely ionisation tracks at the DNA site. This aids the cells in becoming more 437 
responsive and susceptible to radiation, which in turn enhanced the effectiveness of the treatment. 438 
 439 
The radiation enhancement effect of BrUdR has been shown to be independent of the photon energy as 440 
opposed to Ta2O5 NSPs that displayed a radio-enhancing effect only in the MV energy beam (i.e., SER10% of 441 
1.29). The radio enhancing effect of Ta2O5 NSPs found in this study was comparable to a previous research 442 
that reported a SER10% of 1.33 for the thermal decomposition synthesising Ta2O5 NSPs material (Brown et al 443 
2014). 444 
 445 
High Z NSPs in close proximity to the cell when interacting with the beam can trigger the photoelectric or 446 
Compton effects that can cause damage to the surrounding cancerous cells. However, this result did not 447 
account for the absence of the dose enhancement effects of Ta2O5 NSPs at its optimum radiated energy of 448 
150kVp (i.e., SER10% of 1.03). Previous research has shown radiosensitisation effects of the NSPs to be 449 
stronger for low–energy beams (Jain et al 2011). With the Z of Ta2O5 NSPs as high as 73, a promising dose 450 
enhancement is expected for majority of the high-Z elements present in the cells (Kobayashi et al 2010). 451 
Doubling the Z value of the BrUdR compound (Z= 35) and also higher concentration applied, a high SER10% 452 
in kV was also anticipated for Ta2O5 NSPs despite the compound being only in close proximity to the cell 453 
nucleus. However, the finding from this study (see Figure 6) did not demonstrate this.  454 
  455 
Nanoparticles related radiation dose enhancement is predominantly dependent on a number of factors such as 456 
the size of the nanoparticles, the concentration of nanoparticles applied, surface properties of nanoparticles 457 
and the radiation energy (Xu et al 2009). The surface chemical reactivity of Ta2O5 NSPs is neutral and thus 458 
induces very low toxicity (Brown et al 2017). Additionally, the surface properties are mainly concerned with 459 
the approach of binding to the cancerous cells in the theranostic system and this is out of our scope in these 460 
studies. The crystallite size of the Ta2O5 NSPs utilised in this research have a mean size of 50- 100nm and 461 
was irradiated with its optimum 150 kVp X-rays. This corresponds with a previous research that reported 462 
50nm size gold NSPs to achieve the best radiosensitising effect (Chithrani et al 2010). However, other 463 
studies have reported mixed findings in relation to the optimal size of NSPs (Kong et al 2008, Rahman et al 464 
2009, Hainfeld et al 2008). Despite sonicating the Ta2O5 NSPs prior to adding into the cells, the result 465 
obtained in this research following the internalisation of NSPs in the cells after 24 hours was marginally 466 
small. An explanation for this is observed in the confocal images that shows formation of agglomerate of 467 
Ta2O5 NSPs. Hence, the bulk size of the Ta2O5 NSPs absorbed the majority of the low-energy short range 468 
electrons produced by the kV radiation. This subsequently hinders the Ta2O5 NSPs from depositing their 469 
energy on the target cancerous cells (Brown et al 2014 and 2017, McKinnon et al 2016). The result obtained 470 
in this study is significant because it does not follow the conventional finding of other high Z nanoparticles 471 
studies, where radiation dose enhancement is dominant in the kV radiated energy (Algethami et al 2015, 472 
Rahman et al 2009, Luchette et al 2014). This is due to the photoelectric effect which is prevailing until the 473 






































































photon energy reaches 500 keV (Retif et al 2015). Firstly, to achieve a dose enhancement in megavoltage for 474 
Ta2O5 NSPs has more clinical potential than in the kilovoltage region as it could target most of the tumours 475 
localisation. Additionally, to also achieve a negligible dose enhancement in kV for Ta2O5 NSPs, provide 476 
insight for our near future in vivo model to utilise On-Board-kilovoltage imaging system (operating range at 477 
40-150 kVp using a dose ~2 cGy) as a part of the image-guided radiotherapy linear accelerator. The absence 478 
of dose enhancement in the kilovoltage region would not increase energy deposit due to an On-Board-479 
kilovoltage imager which is an advantage in the sense that this dose enhancement would be very difficult to 480 
take into account precisely as current treatment planning systems do not model kilovoltage imaging doses 481 
accurately.   482 
 483 
 484 
Figure 8. Comparison of the sensitisation enhancement ratio (SER10%) for cells pre-treated with (a) 5-485 
FU+BrUdR and (b) 5-FU+Ta2O5 NSPs with and without the individual components of the combination in 486 
their respective optimum 125 and 150 kilovoltage and 10 megavolt photons energy. 487 
 488 
Radiation sensitization enhancements of 5-FU strongly depends on how drastic the damage on the DNA 489 
target induced by the high Z  490 
 491 
To date, the combination of 5-FU with radiation has been extensively used and is the most promising clinical 492 
radiosensitiser (McGinne and Lawrence 2001). In this research, the dose enhancement was not observed in 493 
the 5-FU survival curve, for all radiation energies used. One possible explanation could be that the 494 
concentration of 5-FU used in our studies is 100 times lower than that of the half maximal concentration to 495 
inhibit the biological process (IC50). The 5-FU has shown to enhance the radiation sensitisation of both 496 
BrUdR and Ta2O5 NSPs in both kVp and MV energies (see Figure 6 & 7). Particularly, the synergistic effect 497 
was achieved with the 5-FU+BrUdR in the kVp. The measured values of SER10% for 5-FU+BrUdR and 5-498 
FU+ Ta2O5 NSPs in the kVp (see Tables 1 and 2, and Figure 8) were significantly different with an 499 
incomparable result of 2.11 and 1.10 respectively. This significant difference is hypothesised to be due to 500 
BrUdR creating a more drastic and complex damage to DNA than Ta2O5 NSPs in the kVp. Thus, require a 501 
greater repair process, which can be achieved through lowering the concentration of 5-FU. 502 
 503 
At 10MV, the SER10% for both combinations of 5-FU+BrUdR and 5-FU+Ta2O5 NSPs is measured to be 1.61 504 
and 1.35 respectively (see Figure 8). No significant difference in the degree of enhancement was found 505 
between BrUdR and 5-FU+BrUdR, and Ta2O5 NSPs and 5-FU+Ta2O5 NSPs. That is, both combinations 506 
yielded the same percentage increase by 5% in SER10%. The degree of enhancement was nonsignificant. We 507 
hypothesis the damage induced by the high Z is less drastic and complex in the MV beam. This is due to the 508 







































































damages being from the lower LET secondary electrons. Consequently, the concentration of 5-FU utilised in 509 
this study blocked the repair of radiation injury quite effectively. Nevertheless, 5-FU did display a visible 510 
sensitising effect in both combination in both kV and MV energies. This is evident in the increase in the α 511 
and decrease in β component of the survival curves (see Table 1, 2, & 3). The reason being was that no 512 
shoulder was observed in the survival curves for both combinations, in MV and kV (see Figures 6 and 7). 513 
The shoulder denotes the capacity of cells to repair itself after being damage by radiation, which is a general 514 
characteristic of the cell survival curve after irradiation. In support of this, a study has found the 5-FU drug 515 
to independently decrease the width of the survival curve shoulder as the concentration of the drugs 516 
increased in two human cells lines (Kim et al 1993). 517 
 518 
In this study, the 5-FU drug alone was not found to radiosensitise the cell. As such, the increased sub-lethal 519 
damage achieved in both the 5-FU+BrUdR and the 5FU+Ta2O5 combinations was due to high-Z triggering 520 
the mechanism of 5-FU to inhibit cell repair. The sensitisation mechanism of 5-FU is not fully understood in 521 
the past however different studies including Kim et al (1993) and Nakajima et al (1979) proposed that 5-FU 522 
acted as an inhibitor of cells repair from radiation damage rather than direct enhancement of sub-lethal 523 
damage during exposure to radiation. Our results proven their hypothesis to be true as well as agreed with 524 
what we proposed to happen with the combination of 5-FU with a high-Z in the 10MV irradiated energy. 525 
 526 
In spite of the aforementioned findings, this study found the sensitisation mechanism of the 5-FU drug is 527 
sufficient only in producing a synergistic effect for the 5-FU+BrUdR in the 125 kVp (see Figure 6). Previous 528 
research has shown that for 5-FU to sensitise cells to radiation, a degree of 5-FU toxicity needs to be 529 
achieved (Byfield et al 1982). Translating this to our study means that a higher concentration of 5-FU may 530 
be needed in order to observe radiosensitisation at our irradiated energies and by extension, an accountable 531 
SER10% in its combination with the high-Z. Another research has also demonstrated the 5-FU drug to 532 
efficiently sensitised another radioresistant cancer cell line with 6 MV x-ray at a concentration of 100 µM 533 
(Hajikarimi et al 2004). This concentration is 10000 times higher at a lower irradiated MV energy than what 534 
is used in this study. Similarly, another research also reported a concentration of 5-FU of ≥ 0.1µM to be the 535 
critical combination in radiosensitising a radioresistance colon cancer cell lines (Ojima et al 2006). Hence, in 536 
order to achieve a good synergistic/additive effect between 5-FU and a high-Z in the MV irradiated energies, 537 
a concentration of 5-FU up to at least 100 times higher may need to be trialled. However, the use of this 538 
critical concentration or higher would result in a significant increase in cytotoxicity of cells including the 539 
healthy cells. Alternatively, increasing the concentration of the high Z material in order to create a high LET 540 
electron environment can potentially bestow the synergistic effects in this clinically relevant X-ray energy 541 
field. Future research could possibly examine ways to enhance the effect of cell death in the MV energy 542 
range given that a high-energy beam is currently a more favoured clinical application in the treatment of 543 
deep tumours (>2 cm in depth) compared to conventional kilovoltage beams. Alternatively, kilovoltage 544 
Synchrotron radiation beams, geometrically spaced in Microbeams, would possess the required physical 545 
properties to allow for adequate energy deposition at the tumour combined with exceptional normal tissue 546 
sparing capabilities. Translation of this multimodal treatment to a pre-clinical in vivo model like the well 547 
accepted experimental neuro-oncological model, Fisher 344 rats with 9L brain gliosarcoma, would be an 548 
essential step toward potential future clinical application, allowing for the intrinsic complexity of 549 













































































In this paper, we have experimentally demonstrated the radiosensitisation enhancement effect of BrUdR and 557 
Ta2O5 NSPs, with respect to their Z and location from the cell nucleus. BrUdR has shown to radiosensitise in 558 
both the kVp and MV x-ray beams. The kVp beam interacted with the localised BrUdR, which generated 559 
high LET secondary electrons that created clustered damage on the DNA. The dose enhancement achieved 560 
with the MV beam is hypothesised to be from the non-localised BrUdR. The MV beam interacted with the 561 
BrUdR located in proximity of the DNA, generated low LET but higher kinetic energy secondary electrons 562 
that reached the DNA target to cause sub-lethal damage. Ta2O5 NSPs radiosensitised the 9L cancer cells 563 
selectively in the 10 MV irradiation field. The radiation dose enhancement achieved was from the same type 564 
of secondary electrons generated by the non-localised BrUdR in the MV beam. The formation of Ta2O5 565 
NSPs around the cells absorbed the high LET secondary electrons generated in the kVp beam, scavenged 566 
radiation dose that was to be deposited on the DNA target. These results highlight the importance of high Z 567 
material to be small on the scale that they can be subcellular localised to give radiation dose enhancement in 568 
the kV radiation fields. The dominating factor to dose enhancement for high Z material shifted towards 569 
achieving their distribution within the whole target volume in order to maximise the radiation dose 570 
enhancement in the clinically relevant radiation energy of 10 MV.  571 
 572 
A relevant synergistic effect is achieved only with 5-FU+BrUdR in the kVp radiation. This is due to more 573 
drastic and complex damages induced by BrUdR under the exposure of radiation. This type of damages 574 
achieved by the high LET secondary electron demand a greater repair process. At the 10 MV, the SER10% 575 
obtained for 5-FU+BrUdR and 5-FU+Ta2O5 NSPs is only a marginal increase from their respective high Z 576 
standalone results. The damage induced by the high Z is less substantial in the MV beam. This is due to the 577 
damage being from the lower LET secondary electron generation. These findings prove that the effect of 5-578 
FU is dependent on how severe the damage is on the DNA target. These in turn are dependent on the LET, 579 
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